Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration in established Parkinson's models?

PARTIALLY ADDRESSED

While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development. Gap type: open_question Source paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)

Priority: 0.87 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration in established Parkinson's models? is a 0.87 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration in established Parkinson's models? — INVOKE-2 (completed)

📈 Living Dashboards

0

Hypotheses

0.000

Top Score

0.000

Avg Score

1

Debates

0.54

Avg Quality

60%

Resolution

0

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (19)

PARKIN→ParkinsonUBIQUITIN→ParkinsonMITOPHAGY→Parkinson6-OHDA→ParkinsonMICROGLIA→Parkinson

▸ Show 14 more

AUTOPHAGY→ParkinsonPINK1→ParkinsonNEUROINFLAMMATION→ParkinsonParkinson→AutophagyParkinson→ApoptosisParkinson→Immune ResponsePTEN→ParkinsonPARKINSON'S DISEASE→ParkinsonNRF2→ParkinsonSIRT1→ParkinsonParkinson→MitophagyGENES→ParkinsonParkinson→Oxidative StressParkinson→Nf-Κb

associated with (7)

UBIQUITIN→ParkinsonParkinson→FerroptosisParkinson→ApoptosisParkinson→Amyotrophic Lateral SclerosisNeuroinflammation→Parkinson

▸ Show 2 more

Cancer→ParkinsonAmyotrophic Lateral Sclerosis→Parkinson

causes (1)

LRRK2→Parkinson

regulates (7)

AMYOTROPHIC LATERAL SCLEROSIS→ParkinsonNEURODEGENERATIVE DISORDERS→ParkinsonGENES→ParkinsonParkinson→AutophagyPARKIN→Parkinson

▸ Show 2 more

Parkinson→Oxidative StressPINK1→Parkinson

therapeutic target (16)

APOPTOSIS→ParkinsonNEURODEGENERATIVE DISEASES→ParkinsonNEURODEGENERATION→ParkinsonAUTOPHAGY→ParkinsonPARKINSON'S DISEASE→Parkinson

▸ Show 11 more

AKT→ParkinsonParkinson→Immune ResponseParkinson→ProteasomeDNA→ParkinsonParkinson→AutophagyParkinson→ApoptosisNRF2→ParkinsonParkinson→Oxidative StressParkinson→Blood-Brain BarrierGENES→ParkinsonUBIQUITIN→Parkinson

🕑 Activity Feed

✏ update on knowledge_gap by None 2026-04-25T22:15

🎭 Does RGS6 upregulation or D2 autoreceptor modulation prevent q=0.54 2026-04-25T18:26

✏ update on knowledge_gap by None 2026-04-25T18:26

✏ update on knowledge_gap by None 2026-04-25T18:26

✏ update on knowledge_gap by None 2026-04-22T19:29

✏ update on knowledge_gap by None 2026-04-22T15:44

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps